New leukemia trial aims to help patients stop treatment
NCT ID NCT06958705
Summary
This study is testing if adding a drug called venetoclax for one year to a patient's current BTK inhibitor therapy can lead to a deep remission in Chronic Lymphocytic Leukemia (CLL). The goal is to see if patients can then safely stop all treatment. The study will enroll 79 adults with CLL who have been responding well to a BTK inhibitor alone for at least six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.